Eyepoint Pharmaceuticals, INC

EyePoint announced topline data from its LUGANO Phase 3 trial for DURAVYU in wet AMD, missing the primary endpoint in the full dataset but showing positive results in secondary endpoints and an ad hoc analysis.

EyePoint, Inc. announced its second quarter 2026 financial results, highlighting progress in its DURAVYU clinical trials for wet AMD and DME, with topline data expected soon and a cash runway extending into late 2027.

EyePoint, Inc. announced the completion of enrollment in its pivotal Phase 3 clinical trials for DURAVYU in treating diabetic macular edema (DME), with topline data expected in Q4 2027.

EyePoint, Inc. has entered into a settlement agreement with the U.S. Department of Justice to resolve allegations related to past sales and marketing practices for DEXYCU, agreeing to pay $4.7 million and enter a five-year Corporate Integrity Agreement.

EyePoint announced a positive third consecutive recommendation from its Data Safety Monitoring Committee for the ongoing Phase 3 trials of DURAVYU in wet AMD, reinforcing confidence ahead of mid-2026 topline data.

EyePoint announced its first quarter 2026 financial results, highlighting progress in its Phase 3 wet AMD and DME clinical trials, with significant cash reserves extending runway into late 2027.

EyePoint Pharmaceuticals reported a significant increase in net loss for Q3 2025 and the nine months ended September 30, 2025, driven by accelerated R&D for its lead candidate DURAVYU, while securing a $162.1 million equity financing to extend its cash runway into Q4 2027.

EyePoint Pharmaceuticals reported a significant increase in net loss for Q2 2025 driven by higher research and development costs for its lead drug candidate DURAVYU, despite positive clinical trial progress.

EyePoint Pharmaceuticals' Q1 2025 results show increased revenue driven by royalty income, progress in DURAVYU clinical trials, and a net loss of $45.2 million.

EyePoint Pharmaceuticals reported its Q3 2024 financial results, highlighted by increased R&D spending and progress in its DURAVYU clinical trials.

EyePoint Pharmaceuticals reported its second quarter 2024 financial results, highlighting progress in clinical trials for DURAVYU and a shift in revenue streams following the sale of YUTIQ rights.

EyePoint Pharmaceuticals saw a revenue increase in Q1 2024 primarily due to licensing agreements, while research and development expenses also significantly increased.

EyePoint, Inc. reports a net loss of $232.0 million for fiscal year 2025, driven by increased R&D for its lead candidate DURAVYU, which is progressing in Phase 3 trials for wet AMD and DME.

EyePoint Pharmaceuticals' 10-K filing details the company's financial performance, DURAVYU's clinical advancements, and strategic outlook.

EyePoint Pharmaceuticals' 10-K filing outlines details of their common stock, regulatory environment, and clinical development programs, including EYP-1901.

Jay S. Duker, President and CEO and a Director of EyePoint Pharmaceuticals, Inc., reported multiple transactions in common stock on July 10, 2026.

Ramiro Ribeiro, Chief Medical Officer of EyePoint, Inc., reported transactions involving the acquisition and disposition of company common stock and stock options on June 30, 2026.

EyePoint, Inc. Chief Financial Officer George Elston reported transactions involving common stock and restricted stock units, including shares withheld for tax purposes.

Chief Medical Officer Ramiro Ribeiro exercised options for 2,437 shares of EyePoint, Inc. and subsequently sold them.

EyePoint, Inc. President and CEO Jay S. Duker transferred common stock and stock options valued at over $2.3 million to a family trust for estate planning purposes.

EyePoint, Inc. President and CEO Jay S. Duker reported a planned indirect acquisition of 1,500 common shares at $13.1492, effective March 16, 2026, under a 10b5-1 plan.

EyePoint Pharmaceuticals issues a supplement to its definitive proxy statement to correct an error regarding the company's equity overhang.

EyePoint Pharmaceuticals will hold its annual stockholders meeting virtually on June 18, 2025, to vote on director elections, an incentive plan amendment, executive compensation, and auditor ratification.

EyePoint Pharmaceuticals reports strong progress in 2024, highlighted by the advancement of DURAVYU, a potential best-in-class sustained delivery therapy, into Phase 3 trials for wet AMD and DME, alongside a robust financial position.

EyePoint Pharmaceuticals is asking stockholders to approve amendments to its long-term incentive plan and employee stock purchase plan at the upcoming annual meeting.

EyePoint Pharmaceuticals has filed a definitive proxy statement with the SEC.

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 5.71% of EyePoint, Inc.'s common stock as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership stake of 5.03% in EyePoint Inc., crossing the 5% threshold requiring disclosure.

Commodore Capital LP, along with affiliated entities and individuals, has reported beneficial ownership of 4,250,000 shares, representing 5.1% of EyePoint, Inc.'s common stock.

Adage Capital Management, L.P. and associated individuals have reported beneficial ownership of 3,300,000 shares, representing 3.96% of EyePoint, Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for EyePoint Inc, reporting 0% beneficial ownership following an internal corporate realignment.

Paradigm BioCapital Advisors LP and related entities have disclosed a 5.1% beneficial ownership stake in EyePoint, Inc. common stock.